Skip to main content

Table 4 Overall survival, 7-gene signature, and Kaplan–Meier estimates

From: A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD)

Variables Groups
Training group Low risk (n = 51) High risk (n = 51)
Deaths—no. (%)a 2 15
Data censoredb 49 36
Median overall survival—mo (95% CI) NE NE
The overall survival (95% CI) by Kaplan–Meier estimation
 3.60 mo NA 98 (94.3–1)
 10.70 mo NA 90.2 (82.4–98.7)
 13 mo 98 (94.2–1) 84.3 (74.9–94.9)
 23.57 mo NA 82.3 (72.5–93.5)
 27 mo 96 (90.7–1) 76.2 (65.3–88.9)
 31 mo NA 73.9 (62.6–87.2)
 31.5 mo NA 68.6 (56.4–83.5)
Validation group (TCGA data) Low risk (n = 261) High risk (n = 261)
Deaths—no. (%)a 62 125
Data censoredb 199 136
Median overall survival—mo (95% CI) 77.3 (55.1–NE) 36 (31.6–42.2)
The overall survival (95% CI) by Kaplan–Meier estimation
36–39.8 mo 75.4 (68.77–82.7) 49.9 (42.95–58.1)
77–79 mo 48.7 (38.29–61.8) 25.1 (17.72–35.6)
106–112 mo 42.6 (29.85–60.7) 15.2 (8.21–28.2)
  1. NA indicate that there is no available events
  2. NE represent that the value could not be estimated
  3. aRepresent the hazard ratio for death
  4. bIndicate the date for censorship of patients on the date the patient was last known to be alive